NEW YORK, April 7, 2017 /PRNewswire/ —
On Thursday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.25%; the Dow Jones Industrial Average edged 0.07% higher; and the S&P 500 was up 0.19%. US markets made broad based gains with six out of nine sectors finishing the day in green. Pre-market today, Stock-Callers.com reviews these four Drugs – Generic stocks: Diplomat Pharmacy Inc. (NYSE: DPLO), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), Agile Therapeutics Inc. (NASDAQ: AGRX), and Sophiris Bio Inc. (NASDAQ: SPHS). Learn more about these stocks by accessing their free research reports at:
On Thursday, shares in Flint, Michigan headquartered Diplomat Pharmacy Inc. recorded a trading volume of 621,753 shares. The stock ended the day 0.77% higher at $14.38. The Company’s shares are trading at a PE ratio of 34.57. Diplomat Pharmacy’s stock has gained 9.19% in the past three months. The Company’s shares are trading below its 50-day and 200-day moving averages by 2.68% and 36.53%, respectively. Furthermore, shares of Diplomat Pharmacy, which operates as an independent specialty pharmacy in the US, have a Relative Strength Index (RSI) of 40.53. Free research report on DPLO is available at:
Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc.’s stock finished Thursday’s session 1.50% higher at $13.55 with a total volume of 730,001 shares traded. Momenta Pharma’s shares have gained 39.40% in the past one year. The Company’s shares are trading above its 200-day moving average by 1.13%. Shares of Momenta Pharma, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the US, have an RSI of 37.90. The complimentary research report on MNTA can be downloaded at:
Princeton, New Jersey headquartered Agile Therapeutics Inc.’s stock advanced 2.36%, to close the day at $3.04. The stock recorded a trading volume of 166,220 shares. Agile Therapeutics’ shares have surged 41.40% in the last one month and 20.63% in the previous three months. The Company’s shares are trading 21.56% above its 50-day moving average. Additionally, shares of the Company, which focuses on the development and commercialization of prescription contraceptive products for women, have an RSI of 57.25. Visit us today and access our complete research report on AGRX at:
On Thursday, shares in La Jolla, California-based Sophiris Bio Inc. ended the session 2.68% lower at $2.54 with a total volume of 402,637 shares traded. Sophiris Bio’s shares have gained 2.83% in the last one month and 64.40% in the previous one year. The stock is trading 5.96% below its 50-day moving average and 17.03% below its 200-day moving average. Moreover, shares of the Company, which focuses on the development of products for the treatment of urological diseases, have an RSI of 42.42.
On March 13th, 2017, research firm Rodman & Renshaw initiated a ‘Buy’ rating on the Company’s stock, with a target price of $6 per share. Get free access to your research report on SPHS at: http://stock-callers.com/registration/?symbol=SPHS
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.